BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio11.32
Quick Ratio10.05
Price-To-Earnings
Trailing P/E Ratio-103.62
Forward P/E Ratio160.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.02 million
Price / Sales36.06
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book33.53
Profitability
EPS (Most Recent Fiscal Year)($0.21)
Net Income$-2,510,000.00
Net Margins1.76%
Return on Equity2.24%
Return on Assets1.92%
Miscellaneous
Employees40
Outstanding Shares16,460,000
Market Cap$325.12 million
BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions
What is BioLife Solutions' stock symbol?
BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."
How were BioLife Solutions' earnings last quarter?
BioLife Solutions Inc (NASDAQ:BLFS) posted its quarterly earnings results on Thursday, August, 9th. The medical equipment provider reported $0.05 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.01. The medical equipment provider had revenue of $5.18 million for the quarter, compared to analyst estimates of $5.20 million. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.24%. View BioLife Solutions' Earnings History.
When is BioLife Solutions' next earnings date?
What price target have analysts set for BLFS?
3 brokerages have issued 1-year price targets for BioLife Solutions' stock. Their predictions range from $12.00 to $23.00. On average, they expect BioLife Solutions' share price to reach $17.6667 in the next twelve months. This suggests that the stock has a possible downside of 26.8%. View Analyst Price Targets for BioLife Solutions.
What is the consensus analysts' recommendation for BioLife Solutions?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.
What are Wall Street analysts saying about BioLife Solutions stock?
Here are some recent quotes from research analysts about BioLife Solutions stock:
- 1. Northland Securities analysts commented, "We remain constructive on this name. Besides being a lower-risk diversified pseudo-biotech play, BioLife also has the unique opportunity of increasing its revenues per customer, therefore increasing its product stickiness. the most important takeaway from the company call was the increased focus on M&A. The company announced a $20M investment from an investor, bringing the total ownership of that investor to 14%. This investment allows BioLife to start focus on a few M&A targets pretty aggressively. The goal of an M&A strategy would be to increase the ecosystem in which more dollars per customer can be captured. Currently, BioLife generates about $50 – $100/ customer, and a targeted M&A strategy could help the company go 5 – 10x of current revenues/customer." (8/10/2018)
- 2. Maxim Group analysts commented, "BioLife announced preliminary 1Q18 biopreservation media revenues of $3.8M, up 22% from 4Q17, and above consensus estimates of $3.2M. This is the 11th consecutive quarter of record sales for the company and management lifted 2018 guidance to $14.5M-$15.5M, from $13.6M-$14.7M. We have adjusted our model and increased revenue estimates for 2018 as well as outyears, the net result of which is our price target increases to $9, from $8." (4/2/2018)
Who are some of BioLife Solutions' key competitors?
Some companies that are related to BioLife Solutions include Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), electroCore (ECOR), Vision Sciences (CGNT), Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Fonar (FONR), Semler Scientific (SMLR), Zynex Inc. common stock (ZYXI), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), Viveve Medical (VIVE), IRIDEX (IRIX) and Edap Tms (EDAP).
Who are BioLife Solutions' key executives?
BioLife Solutions' management team includes the folowing people:
- Mr. Michael P. Rice, Pres, CEO & Director (Age 55)
- Mr. Roderick de Greef, CFO & Sec. (Age 58)
- Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 46)
- Ms. Karen Foster, VP of Operations (Age 58)
- Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance
Has BioLife Solutions been receiving favorable news coverage?
Media coverage about BLFS stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioLife Solutions earned a daily sentiment score of 0.15 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 48.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for BioLife Solutions.
Who are BioLife Solutions' major shareholders?
BioLife Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Casdin Capital LLC (6.08%), Essex Investment Management Co. LLC (2.09%), Renaissance Technologies LLC (1.46%), EAM Investors LLC (1.29%), Perkins Capital Management Inc. (1.12%) and Millennium Management LLC (0.93%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.
Which institutional investors are selling BioLife Solutions stock?
BLFS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Janney Montgomery Scott LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.
Which institutional investors are buying BioLife Solutions stock?
BLFS stock was acquired by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Renaissance Technologies LLC, Sandler Capital Management, Perkins Capital Management Inc., Granahan Investment Management Inc. MA, EAM Global Investors LLC, EAM Investors LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for BioLife Solutions.
How do I buy shares of BioLife Solutions?
Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioLife Solutions' stock price today?
One share of BLFS stock can currently be purchased for approximately $24.14.
How big of a company is BioLife Solutions?
BioLife Solutions has a market capitalization of $325.12 million and generates $11.02 million in revenue each year. The medical equipment provider earns $-2,510,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. BioLife Solutions employs 40 workers across the globe.
How can I contact BioLife Solutions?
BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]
MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
